Propionic Acidemia Market Segmentation:
Drug Class Segment Analysis
In terms of drug class, L-carnitine segment is estimated to hold 70% share of the global propionic acidemia market by 2035. L-carnitine is a chemical that's produced in the human brain, liver and kidneys. It's helping the body to make energy out of fat. L-carnitine is a vital element for the health of the heart and brain, muscle activity as well as many different processes in the body. The body is capable of converting L-carnitine into other chemicals called acetylcarnitine, and propionyl. In three patients with Propionic Acidemia and in 3 standard controls, L-Carnitine significantly increased the formation and excretion of short chain acylcarnitine. Acylcarnitine has been found to be propionylcarnitine in patients with proionic acidemia by the use of rapid atom bombardment mass spectrometry and a correlation scan at constant magnet-to-electric field ratio. Mostly acetylcarnitine was absorbed by the normal children.
Distribution Channel Segment Analysis
Based on distribution channel, the retail pharmacy segment is expected to hold a notable share of the global propionic acidemia market by 2035. When patients are discharged from hospital, retail pharmacies play an important role in supplying them with medicinal products. Retail pharmacies offer convenient access to essential medications such as carnitine supplements, vitamins and antibiotics for managing PA symptoms. This can be particularly beneficial for patients in remote areas or those who struggle with transportation to specialized clinics. Retail chains are the biggest and most predominant of the four drug store sorts, speaking to a third of stores and around a third of medicine incomes in 2021.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
